410 related articles for article (PubMed ID: 29797817)
1. Diagnostic Performance and Comparative Evaluation of the Architect, Liaison, and Platelia Epstein-Barr Virus Antibody Assays.
Park Y; Park BG; Ha J; Kim HS
Ann Lab Med; 2018 Sep; 38(5):458-465. PubMed ID: 29797817
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Abbott Architect, Siemens Immulite, bioMerieux Vidas, and Euroimmune assays for determination of Epstein-Barr virus serological diagnosis.
Appak O; Ozkaratas MH; Sayiner AA
J Med Virol; 2021 Nov; 93(11):6309-6316. PubMed ID: 34375007
[TBL] [Abstract][Full Text] [Related]
3. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.
Corrales I; Giménez E; Navarro D
Clin Vaccine Immunol; 2014 May; 21(5):684-8. PubMed ID: 24623623
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Abbott Architect
François C; Segard C; Bouvier M; Stefanski M; Pannier C; Zawadzki P; Roussel C; Hecquet D; Duverlie G; Brochot E; Castelain S
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):96-101. PubMed ID: 29198371
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies].
Altuğlu I; Aksoy A; Zeytinoğlu A; Orman M
Mikrobiyol Bul; 2010 Apr; 44(2):231-6. PubMed ID: 20549957
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the new ARCHITECT EBV assays considering different testing algorithms.
Sickinger E; Berth M; Vockel A; Braun HB; Oer M; Buenning C
Diagn Microbiol Infect Dis; 2014 Jul; 79(3):310-6. PubMed ID: 24809858
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of three different assays for the assessment of Epstein Barr Virus immunological status.
Altuglu I; Bozkurt H; Samlioglu P; Zeytinoglu A
New Microbiol; 2007 Oct; 30(4):393-8. PubMed ID: 18080674
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies.
Bruu AL; Hjetland R; Holter E; Mortensen L; Natås O; Petterson W; Skar AG; Skarpaas T; Tjade T; Asjø B
Clin Diagn Lab Immunol; 2000 May; 7(3):451-6. PubMed ID: 10799460
[TBL] [Abstract][Full Text] [Related]
11. Analytical performance evaluation of the Elecsys Epstein-Barr virus immunoassay panel.
Schulte-Spechtel U; Berth M; Lauseker-Hao Y; Meyer-Schlinkmann K; Bohnert M; Jochum S; Schuhmann K
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115443. PubMed ID: 34304105
[TBL] [Abstract][Full Text] [Related]
12. [Atypical profile problem in serological diagnosis of EBV].
Varıcı Balcı FK; Özbek ÖA; Sayıner AA
Mikrobiyol Bul; 2017 Oct; 51(4):378-386. PubMed ID: 29153068
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
14. Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.
Lupo J; Germi R; Semenova T; Buisson M; Seigneurin JM; Morand P
Clin Vaccine Immunol; 2012 Jun; 19(6):929-34. PubMed ID: 22539474
[TBL] [Abstract][Full Text] [Related]
15. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
16. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections.
de Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Clin Vaccine Immunol; 2011 Mar; 18(3):444-8. PubMed ID: 21191077
[TBL] [Abstract][Full Text] [Related]
18. Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis.
Guerrero-Ramos A; Patel M; Kadakia K; Haque T
Clin Vaccine Immunol; 2014 Jun; 21(6):817-23. PubMed ID: 24695777
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method.
Gärtner BC; Hess RD; Bandt D; Kruse A; Rethwilm A; Roemer K; Mueller-Lantzsch N
Clin Diagn Lab Immunol; 2003 Jan; 10(1):78-82. PubMed ID: 12522043
[TBL] [Abstract][Full Text] [Related]
20. [A comparison of the detection of IgM antibodies against the viral capsid antigen (VCA) of EBV (Epstein-Barr virus) in various groups of patients, using indirect immunofluorescence, indirect ELISA and reverse ELISA. Study of the diagnostic efficacy of the anti-VCA EBV IgM ELISA-VIDITEST kit].
Pumannová M; Rezbová M; Svecová M; Hrbácková H; Novotná M; Ochotná J; Roubalová K
Klin Mikrobiol Infekc Lek; 2004 Aug; 10(4):186-90. PubMed ID: 15328576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
